SAN DIEGO--(BUSINESS WIRE)--AltheaDx, Inc., today announced the successful CLIA validation of a next-generation sequencing (NGS) panel for their pharma services program. This panel enables simultaneous testing of 143 solid tumor genes. The AltheaDx Oncology Panel 150 (AOP 150) Assay is a targeted, NGS assay for drug and companion diagnostic development programs.
The AOP 150 Assay is based on Thermo Fisher Scientific’s Oncomine Comprehensive Assay. It runs on the proven Ion Torrent NGS technology, includes the Ion AmpliSeq library preparation technology, and leverages the Oncomine Knowledgebase, which is one of the world’s largest collections of oncology data long-trusted by pharmaceutical companies.
The AOP 150 Assay is designed to work with minimal sample input per run and is well-suited for analysis of tumor samples extracted from formalin-fixed paraffin-embedded (FFPE) tissue, including small biopsies and fine needle aspirates. With a rapid turnaround time, the AOP 150 assay is capable of detecting thousands of clinically and pharmacologically relevant biomarkers, including single nucleotide somatic variants, insertions and deletions.
The AOP 150 Assay is designed to enable pharmaceutical companies the ability to make evidence-based decisions as part of their clinical trial programs. “We are excited to work with Thermo Fisher in expanding our laboratory offerings in both discovery and pharma services. AOP 150 will enhance our efforts to support drug discovery and clinical research in an effort to improve and personalize patient care in the future,” said Jorge Garces, President and COO of AltheaDx.
“We are pleased that AltheaDx has selected to expand their pharmaceutical services with Oncomine next-generation sequencing assays,” said Mike Nolan, vice president and general manager of Oncology for Thermo Fisher Scientific. “Together, we see many efficiencies in establishing a new paradigm that shifts from one test for one drug, to one test for many targeted therapies within the drug-development process to benefit our pharmaceutical partners and, in the future, the larger clinical cancer community.”
About AltheaDx
AltheaDx is a commercial stage molecular diagnostics company which focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. AltheaDx’s Research Services’ NGS portfolio includes pre-qualified panels such as Cancer Hotspot Panel, (50 genes), CCP (409 genes), NOTCH panel (4 genes), AML panel (260 genes), NOTCH1 CLIA assay, BRCA1/2 and Whole Exome Sequencing (~20,000 genes). AltheaDx’s IDgenetix pharmacogenetic testing portfolio addresses some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. AltheaDx is a CLIA-certified, CAP-accredited, and NY-permitted laboratory located in San Diego, CA. For more information, please visit www.altheadx.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
Forward Looking Statements
This press release may contain forward-looking statements regarding the business strategy of AltheaDx. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity or performance to differ materially from those expressed or implied by these forward looking statements. These statements reflect the views of AltheaDx as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
